Clinical Trial Update: Zr-89 Crefmirlimab Berdoxam and Immuno-Positron Emission Tomography for the Imaging of Patients With Resectable Brain Tumors [Phase 1]

View source ↗

Summary

A Phase 1 imaging trial evaluating a zirconium-89 labeled antibody (Zr-89 Crefmirlimab Berdoxam) for Immuno-PET imaging of resectable brain tumors, including gl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Metastases
• Glioma
• Malignant Brain Neoplasms
• Meningioma

Drugs mentioned

• Zr-89 Crefmirlimab Berdoxam (crefmirlimab berdoxam)

Snippet

Sponsor: Jonsson Comprehensive Cancer Center | Conditions: Glioma, Malignant Brain Neoplasm | Phase 1 | Status: RECRUITING